Additional Lesion Sets in Ablation of Outflow Tract Premature Ventricular Contractions: A Randomized Clinical Trial
Kexin Wang,Fu Yi,Fangyi Xiao,Cao Zou,Yuzhen Zhang,Yuegang Wang,Linsheng Shi,Chengzong Li,Long Chen,Shuanglun Xie,Wenzhi Shen,Ning Zhang,Qiang Wu,Qiang Xu,Yuan Ji,Cheng Wang,Zhiyu Lin,Youquan Wei,Zhongbao Ruan,Yumin Sun,Weizhu Ju,Minglong Chen,OT-PVCs Study Investigators,Caiyi Jin,Jie Li,Shengjie Wu,Jing Zhou,Hairuo Lin,Xiaoli Chen,Xiaoqing Hu,Yaowu Lin,Yuyang Chen,Tong Pan,Xie Yun,Jianshu Chen,Liuyang Wu,Jingcheng Chen,Qingsong Xiong,Jichun Liu,Xiangwei Ding,Bin Cao
DOI: https://doi.org/10.1001/jamacardio.2024.2975
2024-11-01
Abstract:Importance: Recurrence remains a challenge after ablation of outflow tract premature ventricular contractions (OT-PVCs). Although adding additional lesions next to the index effective ablation site is sometimes performed to reinforce the ablation, it remains uncertain whether this approach is effective. Objective: To test the hypothesis that additional ablation lesions would reduce the recurrence rate compared with single-point ablation at the index effective site for the ablation of OT-PVCs. Design, setting, and participants: This study was a multicenter, prospective, randomized clinical trial. Patients receiving their first catheter ablation for OT-PVCs were enrolled from 18 hospitals in China between October 2021 and February 2023. Scheduled follow-up duration was 3 months after the procedure. Intervention: After identifying the target point and eliminating the PVC by a single-point ablation, patients were randomized 1:1 into an additional ablation group or a control group. Main outcomes and measures: The primary end point of the study was freedom from PVC recurrence (≥80% reduction of PVC burden, which is the number of PVCs in 24 hours/total heartbeats in 24 hours × 100%) from baseline to 3 months postprocedure. Results: Of 308 patients enrolled in the study, 286 (mean [SD] age, 49.2 [14.6] years; 173 female [60.5%]) were randomized to the additional ablation or the control group. The additional ablation group had a mean (SD) of 6.3 (1.1) radiofrequency applications, whereas the control group (single-point ablation group) had a mean (SD) of 1 (0) radiofrequency application. After a median (IQR) follow-up of 3.2 (0) months, the rate of freedom from PVCs was significantly higher in the additional ablation group (139 of 142 [97.9%]) compared with the control group (115 of 139 [82.7%]; P < .001). Patients in the additional ablation group also had a more substantial reduction in PVC burden than the control group (mean [SD] reduction, 23.0% [10.5%] vs 19.0% [10.4%]; P = .002). There were no severe periprocedural complications in either group. Conclusions and relevance: This randomized clinical trial showed a benefit of additional ablation in reducing the recurrence of OT-PVCs compared with the single-point ablation strategy, without increased complication risk. Additional ablations surrounding the index effective ablation point should be considered in OT-PVC ablation. Trial registration: Chinese Clinical Trials Registry Identifier: ChiCTR2200055340.